Meta-Analysis

Bardelli, F.; Messori, Andrea; Rampazzo, Roberta; Alberti, Alfredo; Martini, Nello

doi:10.2165/00044011-199510030-00009

Clinical Drug Investigation

1995

DOI: 10.2165/00044011-199510030-00009

|View full text |Cite

Meta-Analysis

F. Bardelli¹,

Andrea Messori²,

Roberta Rampazzo³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1996

1998

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Interferon, Cortisone, and Antivirals in the Treatment of Chronic Viral Hepatitis: A Review of 30 Years of Therapy

Malaguarnera,

Restuccia,

Motta

et al. 1997

Pharmacotherapy

View full text Add to dashboard Cite

Over the last 30 years many approaches have been adopted to treat chronic hepatitis. We conducted a meta‐analysis to assess the efficacy of various types of treatments. We selected 4 studies of cortisone in chronic hepatitis B; 21 trials of interferon treatment, 6 in chronic hepatitis B, 10 in chronic hepatitis C, and 5 in chronic hepatitis D; and 5 of combined cortisone and interferon treatment in chronic hepatitis B. The Mantel‐Haenszel‐Peto method was applied to extrapolated data. We completed the study by analyzing four studies of cortisone treatment of chronic hepatitis C, two of cortisone plus interferon a (IFN‐α) for chronic hepatitis C, and antiviral therapy for hepatitis B, C, and D. Trials administering cortisone for chronic hepatitis B had an overall OR of 0.29 (CI 0.12‐0.73). No virologic remissions were observed in patients with hepatitis C receiving prednisone, even if those with features of autoimmunity achieved a biohumoral sustained response. Overall ORs in the trials were were as follows: IFN for chronic hepatitis B, 0.27 (CI 0.17‐0.46); IFN for chronic hepatitis C, 0.3 (CI 0.21‐0.44); IFN for chronic hepatitis D, 0.16 (CI 0.06‐0.47); and cortisone plus interferon for chronic hepatitis B, 0.25 (CI 0.15‐0.41). Sustained response rates of chronic hepatitis C ranged from 15–24.2%. The only encouraging results were obtained by antivirals. To date the lack of a specific antiviral drug makes it uncertain as to the preferred agent for this disease.

show abstract

Interferon, Cortisone, and Antivirals in the Treatment of Chronic Viral Hepatitis: A Review of 30 Years of Therapy

Malaguarnera,

Restuccia,

Motta

et al. 1997

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

The efficacy of interferon alfa in chronic hepatitis B: a review and meta-analysis

Malaguarnera

Restuccia

Receputo

et al. 1996

Current Therapeutic Research

View full text Add to dashboard Cite

Tacrine Treatment of Alzheimer’s Disease: Many Expectations,Few Certainties

Malaguarnera

Pistone²,

Vinci³

et al. 1998

Neuropsychobiology

View full text Add to dashboard Cite

Quality of life and behavioral functions are severely reduced in patients affected by Alzheimer’s disease (AD). Among the drugs employed in the treatment of this invalidating degenerative dementia, tacrine (THA) seemed to play a possible therapeutic role. Our study was aimed to evaluate the efficacy of THA in the treatment of AD, performing a comparison with lecithin and/or placebo treatment. Five randomized controlled trials on tacrine versus lecithin and/or placebo treatment were randomly selected. Mantel-Haenszel-Peto method was applied. Patients treated with tacrine achieved better results than control subjects (overall OR = 2.34; 95% CI 1.42–3.85); but long-term treatment with tacrine was not significantly more efficacious than placebo. Statistical significance in favor of THA versus other drugs employed was obtained in MMSE and ADAS-Cog tests in the studies carried out by Eagger et al. and Knapp et al. Moreover, Fitten et al. administered the highest tolerated THA dose to only a few patients enrolled in the study. The presence of broad CIs observed in the 5 meta-analytic studies infer non homogeneity of effects of treatment. Solely few patients improved, whereas the clinical conditions of the majority remained stationary. Between 5 and 10% of the outpatients in each single study presented reversible side effects calling for suspension of THA treatment. The optimal dose ranged between 80 and 160 mg THA, but often produced side effects. Comparative trials revealed the reduced efficacy and elevated toxicity of THA treatment, dampening the initial enthusiasm concerning the usefulness of this drug in AD. Furtermore, tacrine-induced side effects provoked many dropouts in all studies investigated. The effectiveness of tacrine treatment in AD disease was not fully confirmed. Other studies are required to identify doses and modalities of administration of this drug in AD.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Meta-Analysis

Cited by 4 publications

References 8 publications

Interferon, Cortisone, and Antivirals in the Treatment of Chronic Viral Hepatitis: A Review of 30 Years of Therapy

Interferon, Cortisone, and Antivirals in the Treatment of Chronic Viral Hepatitis: A Review of 30 Years of Therapy

The efficacy of interferon alfa in chronic hepatitis B: a review and meta-analysis

Tacrine Treatment of Alzheimer’s Disease: Many Expectations,Few Certainties

Contact Info

Product

Resources

About